Thursday, October 15, 2026

Insurance & Risk Management

4 articles

Specialty Insurers Target 20-30% Underwriting Income Growth as Niche Markets Harden

Specialty Insurers Target 20-30% Underwriting Income Growth as Niche Markets Harden

Palomar Holdings projects 20-30% annual net underwriting income growth, driven by 44% premium increases and strategic expansion in crop, earthquake, and surety lines. The specialty insurer doubled crop premiums to $120 million and acquired Gray Casualty to strengthen its surety platform, targeting $500 million in crop business over the intermediate term.

ViaNews Editorial Team (Finance)•
ACES Specialty Insurance launches with $30M capital to underwrite catastrophe-prone markets

ACES Specialty Insurance launches with $30M capital to underwrite catastrophe-prone markets

American Coastal's new E&S carrier ACES Specialty Insurance Company plans to launch with $30 million policyholder surplus to write commercial property risks in Florida, Texas, and South Carolina. The capitalization level raises questions about loss absorption capacity as reinsurance costs climb and catastrophe bond pricing remains elevated.

ViaNews Editorial Team (Finance)•
Insurance Firms Post 14% Book Value Gains While Signaling Growth Moderation Ahead

Insurance Firms Post 14% Book Value Gains While Signaling Growth Moderation Ahead

Major insurers report strong 2025 results with Loews Corporation's book value up 14% year-over-year and Brookfield Wealth Solutions holding $35 billion cash reserves. OP Pohjola projects 2026 operating profit will remain at "good levels" but fall below 2025 performance, signaling a maturing earnings cycle. Fairfax Financial launched a C$650 million senior notes offering to refinance debt and pursue acquisitions.

ViaNews Editorial Team (Finance)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com